Overview

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
ENROLLING_BY_INVITATION

Trial end date:
2030-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Fujian Medical University

Treatments:

lenvatinib
Oxaliplatin